Search alternatives:
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
-
19701
-
19702
-
19703
DataSheet_1_Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis.docx
Published 2023“…Rigosertib (ON 01910.Na) was associated with a decreased risk of AEs in digestive system (ES, 0.103; 95% CIs, 0.059-0.147), but BI 2536 and Volasertib (BI 6727) increased risk of AEs in blood system (ES, 0.399; 95% CIs, 0.294-0.504). …”
-
19704
M-TUBE is a fabrication-free, microfluidics tubing-based bacterial electroporation device that is simple to assemble and exhibits higher electroporation efficiency than cuvettes.
Published 2022“…Transformation was dependent on the electric field. For M-TUBE devices, a voltage of ±2.50 kV (AC field) was applied, which results in an electric field of 8.33 kV/cm. …”
-
19705
DataSheet_2_Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis.pdf
Published 2023“…Rigosertib (ON 01910.Na) was associated with a decreased risk of AEs in digestive system (ES, 0.103; 95% CIs, 0.059-0.147), but BI 2536 and Volasertib (BI 6727) increased risk of AEs in blood system (ES, 0.399; 95% CIs, 0.294-0.504). …”
-
19706
-
19707
-
19708
-
19709
NK-DLI<sub>IL-2 stim</sub> but not NK-DLI<sub>unstim</sub> led to a considerable disappearance of NK cells from PB.
Published 2011“…Striped bars indicate estimated patient's PB volume and peripheral NK cell count at the time point of NK-DLI infusion. <u>Left graph</u> shows a mean 5.5-fold reduction of absolute NK cell count in the PB as early as 10 min post NK-DLI<sub>IL-2 stim</sub> compared to a 1.2-fold decrease for NK-DLI<sub>unstim</sub>. …”
-
19710
Fig 6 -
Published 2024“…Results of the linear mixed models (differences in LS means <i>versus</i> 3-hour and 20°C baseline) for each marker by time point and temperature are presented in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0301845#pone.0301845.s010" target="_blank">S10 Table</a>. …”
-
19711
-
19712
Data Sheet 1_Development of a rapid fiber-detection system using artificial intelligence in phase-contrast microscope images of actual atmospheric samples.pdf
Published 2025“…Additionally, since the counting process relies on visual fiber counting, analytical accuracy can be decreased due to factors such as analyst fatigue. Ambient air samples or air samples collected near demolition sites were observed and acquired using a phase contrast microscope. …”
-
19713
Genetic deletion and pharmacological inhibition of P2rx7 results in antidepressant phenotype in mice using the TST (A, B) and SPT (C–H) tests.
Published 2013“…<p>A/Genetic disruption of P2rx7 expression decreases basal immobility in the TST (n = 6,10, ***P<0.001 vs. …”
-
19714
Data_Sheet_1_A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes.DOC...
Published 2022“…<p>The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg sitagliptin (n = 60) or the placebo (n = 60) for 56 weeks and lifestyle modification in both groups. …”
-
19715
Table_1_A Novel Natural Antimicrobial Can Reduce the in vitro and in vivo Pathogenicity of T6SS Positive Campylobacter jejuni and Campylobacter coli Chicken Isolates.DOCX
Published 2018“…Furthermore, the reduced adhesion and invasion is associated with a significant decrease in bacterial motility of both isolates (p < 0.05–p < 0.001) in vitro. …”
-
19716
Image_2_A Novel Natural Antimicrobial Can Reduce the in vitro and in vivo Pathogenicity of T6SS Positive Campylobacter jejuni and Campylobacter coli Chicken Isolates.JPEG
Published 2018“…Furthermore, the reduced adhesion and invasion is associated with a significant decrease in bacterial motility of both isolates (p < 0.05–p < 0.001) in vitro. …”
-
19717
Image_1_A Novel Natural Antimicrobial Can Reduce the in vitro and in vivo Pathogenicity of T6SS Positive Campylobacter jejuni and Campylobacter coli Chicken Isolates.JPEG
Published 2018“…Furthermore, the reduced adhesion and invasion is associated with a significant decrease in bacterial motility of both isolates (p < 0.05–p < 0.001) in vitro. …”
-
19718
-
19719
-
19720
Data Sheet 1_Analysis of serum amino acids and tryptophan metabolites to predict hepatic encephalopathy in portal hypertension patients receiving a transjugular intrahepatic portal...
Published 2025“…The aim of this study is to identify the potential biomarker that can predict the occurence of HE after TIPS in patients with portal hypertension (PH), and provide the theoretical support for early clinical diagnosis and prevention.</p>Methods<p>A total of 50 patients with PH underwent TIPS were enrolled with completed clinical information in this study, and they were divided into two groups with or without the complications of HE.…”